Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

Charles A. Herzog; Richard W. Asinger; Alan K. Berger; David M. Charytan; Javier Díez; Robert G. Hart; Kai Uwe Eckardt; Bertram L. Kasiske; Peter A. McCullough; Rod S. Passman; Stephanie S. Deloach; Patrick H. Pun; Eberhard Ritz

doi:10.1038/ki.2011.223

Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

Charles A. Herzog^*, Richard W. Asinger, Alan K. Berger, David M. Charytan, Javier Díez, Robert G. Hart, Kai Uwe Eckardt, Bertram L. Kasiske, Peter A. McCullough, Rod S. Passman, Stephanie S. Deloach, Patrick H. Pun, Eberhard Ritz

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Article › peer-review

749 Scopus citations

Abstract

Cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD) is high, and the presence of CKD worsens outcomes of cardiovascular disease (CVD). CKD is associated with specific risk factors. Emerging evidence indicates that the pathology and manifestation of CVD differ in the presence of CKD. During a clinical update conference convened by the Kidney Disease: Improving Global Outcomes (KDIGO), an international group of experts defined the current state of knowledge and the implications for patient care in important topic areas, including coronary artery disease and myocardial infarction, congestive heart failure, cerebrovascular disease, atrial fibrillation, peripheral arterial disease, and sudden cardiac death. Although optimal strategies for prevention, diagnosis, and management of these complications likely should be modified in the presence of CKD, the evidence base for decision making is limited. Trials targeting CVD in patients with CKD have a large potential to improve outcomes.

Original language	English (US)
Pages (from-to)	572-586
Number of pages	15
Journal	Kidney international
Volume	80
Issue number	6
DOIs	https://doi.org/10.1038/ki.2011.223
State	Published - Sep 2 2011

Funding

PHP has received research funding from Satellite Health Care. BLK has received research funding from Bristol-Myers Squibb and Genzyme and is a paid advisor for Litholink (Lab Corp). RGH has received research consulting fees from Boehringer Ingleheim. RWA is a paid advisor for Atritech. RSP receives research support, speaker's fees, and consulting fees from Medtronic. K-UE has received lecture or consulting fees from Amgen, Bayer, Genzyme and GSK, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis. CAH has received research support from Amgen and Johnson & Johnson and honoraria from UpToDate, is a consultant for Amgen, CorMedix, Abbott Labs, FibroGen, Affymax, Fresenius, and Merck, and has equity interest in Cambridge Heart, Merck, Boston Scientific, and J&J. All other authors declared no competing interests. This conference was sponsored by KDIGO and was partially supported by unrestricted educational grants from Novartis, Takeda, and Abbott.

Keywords

atrial fibrillation
heart failure
myocardial infarction
peripheral arterial disease
stroke
sudden death

ASJC Scopus subject areas

Nephrology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/ki.2011.223

Cite this

Herzog, C. A., Asinger, R. W., Berger, A. K., Charytan, D. M., Díez, J., Hart, R. G., Eckardt, K. U., Kasiske, B. L., McCullough, P. A., Passman, R. S., Deloach, S. S., Pun, P. H., & Ritz, E. (2011). Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international, 80(6), 572-586. https://doi.org/10.1038/ki.2011.223

@article{398f2bf4b5fb4eaea31e45ea177e1009,

title = "Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)",

abstract = "Cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD) is high, and the presence of CKD worsens outcomes of cardiovascular disease (CVD). CKD is associated with specific risk factors. Emerging evidence indicates that the pathology and manifestation of CVD differ in the presence of CKD. During a clinical update conference convened by the Kidney Disease: Improving Global Outcomes (KDIGO), an international group of experts defined the current state of knowledge and the implications for patient care in important topic areas, including coronary artery disease and myocardial infarction, congestive heart failure, cerebrovascular disease, atrial fibrillation, peripheral arterial disease, and sudden cardiac death. Although optimal strategies for prevention, diagnosis, and management of these complications likely should be modified in the presence of CKD, the evidence base for decision making is limited. Trials targeting CVD in patients with CKD have a large potential to improve outcomes.",

keywords = "atrial fibrillation, heart failure, myocardial infarction, peripheral arterial disease, stroke, sudden death",

author = "Herzog, {Charles A.} and Asinger, {Richard W.} and Berger, {Alan K.} and Charytan, {David M.} and Javier D{\'i}ez and Hart, {Robert G.} and Eckardt, {Kai Uwe} and Kasiske, {Bertram L.} and McCullough, {Peter A.} and Passman, {Rod S.} and Deloach, {Stephanie S.} and Pun, {Patrick H.} and Eberhard Ritz",

note = "Funding Information: PHP has received research funding from Satellite Health Care. BLK has received research funding from Bristol-Myers Squibb and Genzyme and is a paid advisor for Litholink (Lab Corp). RGH has received research consulting fees from Boehringer Ingleheim. RWA is a paid advisor for Atritech. RSP receives research support, speaker's fees, and consulting fees from Medtronic. K-UE has received lecture or consulting fees from Amgen, Bayer, Genzyme and GSK, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis. CAH has received research support from Amgen and Johnson & Johnson and honoraria from UpToDate, is a consultant for Amgen, CorMedix, Abbott Labs, FibroGen, Affymax, Fresenius, and Merck, and has equity interest in Cambridge Heart, Merck, Boston Scientific, and J&J. All other authors declared no competing interests. This conference was sponsored by KDIGO and was partially supported by unrestricted educational grants from Novartis, Takeda, and Abbott. ",

year = "2011",

month = sep,

day = "2",

doi = "10.1038/ki.2011.223",

language = "English (US)",

volume = "80",

pages = "572--586",

journal = "Kidney international",

issn = "0085-2538",

publisher = "Elsevier B.V.",

number = "6",

}

Herzog, CA, Asinger, RW, Berger, AK, Charytan, DM, Díez, J, Hart, RG, Eckardt, KU, Kasiske, BL, McCullough, PA, Passman, RS, Deloach, SS, Pun, PH & Ritz, E 2011, 'Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)', Kidney international, vol. 80, no. 6, pp. 572-586. https://doi.org/10.1038/ki.2011.223

TY - JOUR

T1 - Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease

T2 - Improving Global Outcomes (KDIGO)

AU - Herzog, Charles A.

AU - Asinger, Richard W.

AU - Berger, Alan K.

AU - Charytan, David M.

AU - Díez, Javier

AU - Hart, Robert G.

AU - Eckardt, Kai Uwe

AU - Kasiske, Bertram L.

AU - McCullough, Peter A.

AU - Passman, Rod S.

AU - Deloach, Stephanie S.

AU - Pun, Patrick H.

AU - Ritz, Eberhard

N1 - Funding Information: PHP has received research funding from Satellite Health Care. BLK has received research funding from Bristol-Myers Squibb and Genzyme and is a paid advisor for Litholink (Lab Corp). RGH has received research consulting fees from Boehringer Ingleheim. RWA is a paid advisor for Atritech. RSP receives research support, speaker's fees, and consulting fees from Medtronic. K-UE has received lecture or consulting fees from Amgen, Bayer, Genzyme and GSK, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis. CAH has received research support from Amgen and Johnson & Johnson and honoraria from UpToDate, is a consultant for Amgen, CorMedix, Abbott Labs, FibroGen, Affymax, Fresenius, and Merck, and has equity interest in Cambridge Heart, Merck, Boston Scientific, and J&J. All other authors declared no competing interests. This conference was sponsored by KDIGO and was partially supported by unrestricted educational grants from Novartis, Takeda, and Abbott.

PY - 2011/9/2

Y1 - 2011/9/2

N2 - Cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD) is high, and the presence of CKD worsens outcomes of cardiovascular disease (CVD). CKD is associated with specific risk factors. Emerging evidence indicates that the pathology and manifestation of CVD differ in the presence of CKD. During a clinical update conference convened by the Kidney Disease: Improving Global Outcomes (KDIGO), an international group of experts defined the current state of knowledge and the implications for patient care in important topic areas, including coronary artery disease and myocardial infarction, congestive heart failure, cerebrovascular disease, atrial fibrillation, peripheral arterial disease, and sudden cardiac death. Although optimal strategies for prevention, diagnosis, and management of these complications likely should be modified in the presence of CKD, the evidence base for decision making is limited. Trials targeting CVD in patients with CKD have a large potential to improve outcomes.

AB - Cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD) is high, and the presence of CKD worsens outcomes of cardiovascular disease (CVD). CKD is associated with specific risk factors. Emerging evidence indicates that the pathology and manifestation of CVD differ in the presence of CKD. During a clinical update conference convened by the Kidney Disease: Improving Global Outcomes (KDIGO), an international group of experts defined the current state of knowledge and the implications for patient care in important topic areas, including coronary artery disease and myocardial infarction, congestive heart failure, cerebrovascular disease, atrial fibrillation, peripheral arterial disease, and sudden cardiac death. Although optimal strategies for prevention, diagnosis, and management of these complications likely should be modified in the presence of CKD, the evidence base for decision making is limited. Trials targeting CVD in patients with CKD have a large potential to improve outcomes.

KW - atrial fibrillation

KW - heart failure

KW - myocardial infarction

KW - peripheral arterial disease

KW - stroke

KW - sudden death

UR - http://www.scopus.com/inward/record.url?scp=80052296951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052296951&partnerID=8YFLogxK

U2 - 10.1038/ki.2011.223

DO - 10.1038/ki.2011.223

M3 - Article

C2 - 21750584

AN - SCOPUS:80052296951

SN - 0085-2538

VL - 80

SP - 572

EP - 586

JO - Kidney international

JF - Kidney international

IS - 6

ER -

Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this